Oramed Pharmaceuticals Inc. ORMP
4.73
(0.06)
(1.25%)
as of 25 Sep
- Market cap
- $199.3M
- P/E
- 1.1×
Follow ORMP
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.77 | 6.23 | 6.60 | 22.01 | |
Current Ratio |
4.98 | 6.45 | 6.98 | 22.25 | |
Net Debt/EBITDA |
18.51 | 18.14 | 22.31 | 56.21 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | (0.08) | (0.05) | (0.03) | |
Capex/Depreciation |
(0.06) | (0.17) | (0.07) | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
0.00 | (0.07) | (0.01) | (0.04) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | (0.07) | (0.01) | (0.04) | |
Cash per Share |
1.23 | 1.61 | 3.04 | 3.23 | |
Shareholders Equity per Share |
7.74 | 5.84 | 4.82 | 4.85 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.74 | 5.84 | 4.82 | 4.85 | |
Free Cash Flow |
(0.20) | (2.92) | (0.47) | (1.62) | |
Working Capital |
42.68 | 57.59 | 114.19 | 130.00 | |
Capital Expenditures |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Current Asset Value |
1.24 | 37.58 | 102.15 | 117.95 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | |
| Other line items | |||||
Average Receivables |
0.52 | — | — | — | |
Average Payables |
5.35 | 6.92 | 6.16 | 4.95 | |
Average Assets |
265.66 | 208.19 | 193.07 | 192.79 | |
Average Common Equity |
235.53 | 189.09 | 172.55 | 178.93 |
Columns are period end dates